Globus Medical Inc. Class A Common Stock vs Hecla Mining Company Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Hecla Mining Company Common Stock trades at $15.29 (market cap $10.01B). The key difference: Globus Medical Inc. Class A Common Stock and Hecla Mining Company Common Stock are close in size by market cap, and Hecla Mining Company Common Stock pays a 0.1% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Hecla Mining Company Common Stock for 3 Days on average.
| GMED | HL | |
|---|---|---|
Market Cap | $10.25B | $10.01B |
Volume | 1,059,528 | 34,838,150 |
Sector | Health | Basic Materials |
52-Week High | $96.82 | $31.81 |
52-Week Low | $58.33 | $11.97 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $9.76B | $9.54B |
Dividend Yield | — | 0.1% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Hecla Mining (HL) trades at $16.18, down 3.92% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 51.68% gross margin and 19.15% net income margin, but recent quarterly earnings missed expectations. Positive news highlights a debt-free balance sheet and organic growth targeting over 20 million silver ounces, while institutional activity includes new investments from Bank of America and AlphaGrep.
The outlook is mixed: analyst consensus is a Buy with a $23.44 price target, implying 45% upside, but technical indicators signal near-term pressure. Key risks include silver price volatility and execution of growth projects. The stock presents a value opportunity for long-term investors if operational targets are met.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Hecla Mining is a precious metals producer focused on silver and gold. It operates mines in the United States and Canada.
Read more on HL →